(Lys8-acetyl-Lys9)-Neurotensin (8-13), MS Grade Peptide
Replacement of the Lys8-Lys9 peptide bond by the CH2NH bond produced an analog with quite interesting pharmacological properties. This degradation-resistant compound was the most active in the binding and biological assays. It exhibited higher binding and biological potencies than neurotensin. It was also about 10 times more potent than neurotensin (8-13) in the bioassay, whereas both peptides were equipotent in the binding assay.